These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 11522537

  • 1. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission.
    Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, Schiavone EM, Pollio F, Palmieri S, Gianfaldoni G, Leoni F.
    Haematologica; 2001 Aug; 86(8):814-20. PubMed ID: 11522537
    [Abstract] [Full Text] [Related]

  • 2. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 4. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J.
    Neoplasma; 2005 May; 52(5):411-4. PubMed ID: 16151586
    [Abstract] [Full Text] [Related]

  • 5. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.
    Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordigoni P, Gandemer V, Thuret I, Dalle JH, Piguet C, Pautard B, Baruchel A, Leverger G, French Society of Pediatric Hematology and Immunology.
    J Clin Oncol; 2003 Dec 01; 21(23):4377-85. PubMed ID: 14645428
    [Abstract] [Full Text] [Related]

  • 6. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y, Auvrignon A, Leblanc T, Michel G, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Mèchinaud F, Lamagnere JP, Piguet Ch, Couillaud G, Pautard B, Baruchel A, Leverger G, Group LAME, French Society of Pediatric Hematology and Immunology.
    Ann Hematol; 2004 Dec 01; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [Abstract] [Full Text] [Related]

  • 7. Survival of elderly patients with acute myeloid leukemia.
    Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, Spadano A, Tosti ME, Visani G, Mele A, Mandelli F.
    Haematologica; 2004 Mar 01; 89(3):296-302. PubMed ID: 15020267
    [Abstract] [Full Text] [Related]

  • 8. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H.
    Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664
    [Abstract] [Full Text] [Related]

  • 9. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lübbert M.
    Ann Hematol; 2003 Jul 01; 82(7):381-9. PubMed ID: 12756497
    [Abstract] [Full Text] [Related]

  • 10. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 11. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
    Ferrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F.
    Hematol Oncol; 2008 Jun 01; 26(2):104-7. PubMed ID: 18271064
    [Abstract] [Full Text] [Related]

  • 12. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Sep 01; 23(3):447-54. PubMed ID: 15595635
    [Abstract] [Full Text] [Related]

  • 13. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.
    Eur J Haematol; 2009 Aug 01; 83(2):99-107. PubMed ID: 19385987
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Aug 20; 23(24):5705-17. PubMed ID: 16110030
    [Abstract] [Full Text] [Related]

  • 15. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 20; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
    Ferrara F, Palmieri S, Mele G.
    Haematologica; 2004 Aug 20; 89(8):998-1008. PubMed ID: 15339685
    [Abstract] [Full Text] [Related]

  • 17. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Dec 20; 30(12):885-91. PubMed ID: 12476281
    [Abstract] [Full Text] [Related]

  • 18. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):427-36. PubMed ID: 15380576
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N, Acute Leukemia French Association, Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS), Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup.
    J Clin Oncol; 2009 Oct 01; 27(28):4747-53. PubMed ID: 19720919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.